Mary Baron Nelson1, Peggy Compton2, Paul M Macey3, Sunita K Patel4, Eufemia Jacob5, Sharon O'Neil6, Jennifer Ogren5, Jonathan L Finlay7, Ronald M Harper8. 1. Children's Hospital Los Angeles, Los Angeles, CA, USA UCLA School of Nursing, Los Angeles, CA, USA mbnelson@chla.usc.edu. 2. UCLA School of Nursing, Los Angeles, CA, USA Georgetown University, Washington, DC, USA. 3. UCLA School of Nursing, Los Angeles, CA, USA David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. 4. City of Hope, Duarte, CA, USA. 5. UCLA School of Nursing, Los Angeles, CA, USA. 6. Children's Hospital Los Angeles, Los Angeles, CA, USA. 7. Nationwide Children's Hospital, Columbus, OH, USA. 8. David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Abstract
BACKGROUND: Childhood brain tumor survivors (CBTS) often experience treatment-related neurocognitive deficits affecting quality of life (QOL), but systemic chemotherapy contributions to outcomes are unclear. Our objective was to relate brain tissue changes to neurocognitive and QOL effects after systemic myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue in CBTS. PROCEDURE: Regional brain volumes and diffusion tensor indices were correlated with neurocognitive, behavioral, and QOL measures, and compared between 8 CBTS (mean age 8.5 years, mean age at diagnosis 32 months), and 9 healthy controls (mean 9.3 years). RESULTS: Overall QOL, school, and psychosocial functioning were significantly lower in patients (P < .05). Most patients scored within normative ranges on neurocognitive and behavioral assessment. Elevated mean diffusivity and decreased fractional anisotropy, indicating gray and white matter injury, respectively, appeared in memory and executive functioning areas. Low scores on Inhibition on the Neuropsychological Assessment-II were correlated with elevated mean diffusivity in prefrontal cortex. CONCLUSIONS: Brain injury, decreased QOL, and to a lesser extent, executive functioning deficits appear in CBTS treated with myeloablative chemotherapy and autologous hematopoietic progenitor cell rescue. Early cognitive and psychological assessment and intervention are warranted in this population.
BACKGROUND: Childhood brain tumor survivors (CBTS) often experience treatment-related neurocognitive deficits affecting quality of life (QOL), but systemic chemotherapy contributions to outcomes are unclear. Our objective was to relate brain tissue changes to neurocognitive and QOL effects after systemic myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue in CBTS. PROCEDURE: Regional brain volumes and diffusion tensor indices were correlated with neurocognitive, behavioral, and QOL measures, and compared between 8 CBTS (mean age 8.5 years, mean age at diagnosis 32 months), and 9 healthy controls (mean 9.3 years). RESULTS: Overall QOL, school, and psychosocial functioning were significantly lower in patients (P < .05). Most patients scored within normative ranges on neurocognitive and behavioral assessment. Elevated mean diffusivity and decreased fractional anisotropy, indicating gray and white matter injury, respectively, appeared in memory and executive functioning areas. Low scores on Inhibition on the Neuropsychological Assessment-II were correlated with elevated mean diffusivity in prefrontal cortex. CONCLUSIONS:Brain injury, decreased QOL, and to a lesser extent, executive functioning deficits appear in CBTS treated with myeloablative chemotherapy and autologous hematopoietic progenitor cell rescue. Early cognitive and psychological assessment and intervention are warranted in this population.
Authors: R K Mulhern; S L Palmer; W E Reddick; J O Glass; L E Kun; J Taylor; J Langston; A Gajjar Journal: J Clin Oncol Date: 2001-01-15 Impact factor: 44.544
Authors: Leanne Embry; Robert D Annett; Alicia Kunin-Batson; Sunita K Patel; Stephen Sands; Gregory Reaman; Robert B Noll Journal: Pediatr Blood Cancer Date: 2012-05-03 Impact factor: 3.167
Authors: Bonnie J Nagel; Shawna L Palmer; Wilburn E Reddick; John O Glass; Kathleen J Helton; Shengjie Wu; Xiaoping Xiong; Larry E Kun; Amar Gajjar; Raymond K Mulhern Journal: AJNR Am J Neuroradiol Date: 2004-10 Impact factor: 3.825
Authors: Nikos Makris; Joseph Biederman; Eve M Valera; George Bush; Jonathan Kaiser; David N Kennedy; Verne S Caviness; Stephen V Faraone; Larry J Seidman Journal: Cereb Cortex Date: 2006-08-18 Impact factor: 5.357
Authors: Antje Wick; Wolfgang Wick; Johannes Hirrlinger; Ellen Gerhardt; Ralf Dringen; Johannes Dichgans; Michael Weller; Jörg B Schulz Journal: J Neurochem Date: 2004-12 Impact factor: 5.372
Authors: Gregory T Armstrong; Qi Liu; Yutaka Yasui; Sujuan Huang; Kirsten K Ness; Wendy Leisenring; Melissa M Hudson; Sarah S Donaldson; Allison A King; Marilyn Stovall; Kevin R Krull; Leslie L Robison; Roger J Packer Journal: J Natl Cancer Inst Date: 2009-06-17 Impact factor: 11.816
Authors: Kevin R Krull; Kristina K Hardy; Lisa S Kahalley; Ilse Schuitema; Shelli R Kesler Journal: J Clin Oncol Date: 2018-06-06 Impact factor: 44.544
Authors: Mary C Baron Nelson; Sharon H O'Neil; Jeffrey Tanedo; Sofia Dhanani; Jemily Malvar; Christopher Nuñez; Marvin D Nelson; Benita Tamrazi; Jonathan L Finlay; Vidya Rajagopalan; Natasha Lepore Journal: Pediatr Blood Cancer Date: 2020-11-29 Impact factor: 3.167